Boston Scientific Corp. took a big step to stay competitive in the increasingly value-based health care sector last month, announcing a joint project with Accenture PLC to develop a service to improve the management of post-discharge heart failure (HF) patients.
The project, which the companies are rolling out globally, targets the total cost-of-care management of a patient group that accounts for an average of 2% of health care spending and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?